Table of Contents
Kyverna Therapeutics is emerging as one of the most closely watched players in autoimmune cell therapy.
Their CD19 CAR-T program KYV-101 is advancing toward registrational studies in stiff person syndrome and myasthenia gravis.
Fresh momentum from Jefferies and a new $150 million non-dilutive financing has extended its runway into 2027.
This positions Kyverna as a potential first-mover in durable, drug-free remission for autoimmune disease.
At Jefferies 2025, I had the pleasure of catching up with CEO Warner Biddle, who gave me the full scoop.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
